Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 54.40
- Piotroski Score 4.00
- Grade Neutral
- Symbol (ELYM)
- Company Eliem Therapeutics, Inc.
- Price $5.11
- Changes Percentage (-0.97%)
- Change -$0.05
- Day Low $5.00
- Day High $5.26
- Year High $11.55
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.52
- Trailing P/E Ratio -17.08
- Forward P/E Ratio -17.08
- P/E Growth -17.08
- Net Income $-35,119,000
Income Statement
Quarterly
Annual
Latest News of ELYM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231m
Private equity firms hold the most power in Eliem Therapeutics with a 53% ownership stake, while institutions and hedge funds also have significant shares. The top 2 shareholders collectively control ...
By Yahoo! Finance | 6 days ago -
EVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM)
Eliem Therapeutics Inc's insider, Valerie Morisset, recently sold 50,000 shares, owning 202,306 now. With a total of 310,650 shares sold in a year, the trend shows more sells than buys....
By Yahoo! Finance | 2 months ago -
Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...
Eliem Therapeutics Inc (NASDAQ:ELYM) saw an insider sale by EVP Valerie Morisset, who sold 92,377 shares at $7.04 each, totaling $650,334....
By Yahoo! Finance | 2 months ago
